Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports

R Andrew Moore , Sheena Derry and Henry J McQuay

Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospital, The Churchill, Oxford OX3 7LJ, UK

author email corresponding author email

Arthritis Research & Therapy 2008, 10:R53doi:10.1186/ar2422


Published:	8 May 2008

Additional files

Additional file 1:

Details of the randomized trials included in the review. The file contains information on each included study, with reference, quality score, design, treatments, main results and comments.

Format: PDF Size: 57KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 2:

Discontinuation rates over 12 weeks because of lack of efficacy in trials conducted over 4 to 12 weeks. The file contains information on percentage of patients not discontinued because of lack of efficacy for weeks 1 to 12, by treatment.

Format: PDF Size: 22KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 3:

Discontinuation rates over 12 weeks because of adverse events in trials conducted over 4 to 12 weeks. The file contains information on percentage of patients not discontinued because of adverse events for weeks 1 to 12, by treatment.

Format: PDF Size: 22KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 4:

Comparison between meta-analyses of etoricoxib, valdecoxib, and celecoxib trials. The file contains information on percentage of patients discontinued by end of trial in meta-analyses of etoricoxib, valdecoxib, and celecoxib trials.

Format: PDF Size: 27KB Download file

This file can be viewed with: Adobe Acrobat Reader